To identify in vitro inhibitors of xanthine crystallization that have potential for inhibiting the formation of xanthine crystals in urine and preventing the development of the renal calculi in patients with xanthinuria.
Introduction
Xanthine urolithiasis is an infrequent type of renal stone formation caused by xanthinuria, a rare hereditary disorder. An affected patient has a deficiency of xanthine oxidase, resulting in hypouricemia and hypouricosuria (1, 2) . Symptom onset can occur at any age. Approximately 50% of patients with classical hereditary xanthinuria present with urinary tract infections, hematuria, renal colic, acute renal failure, and urolithiasis.
A small number of patients also develop renal failure, arthropathy, myopathy, or duodenal ulcer (1, 2) . Hereditary xanthinuria is caused by a mutation of xanthine dehydrogenase (XDH, 2p23.1) or molybdenum cofactor sulfurase (MOCOS, 18q12.2) (3) (4) (5) (6) . These mutations lead to reduced degradation of hypoxanthine and xanthine to uric acid, and the accumulation of these two metabolites. Classically, Type I xanthinuria is caused by an XDH mutation and a deficit of xanthine dehydrogenase/oxidase, whereas Type II xanthinuria is caused by deficits of xanthine dehydrogenase and aldehyde oxidase due to an MOCOS mutation. These different enzyme deficiencies lead to a clinically identical phenotype.
The diagnosis of this disorder is based on plasma and urine levels of uric acid. If an individual has abnormally low values, then clinicians measure urine and plasma xanthine and hypoxanthine levels. Approximately half of these patients have xanthine urolithiasis (7) , and some of these patients can progress to renal failure.
The only recommended treatment for patients with xanthinuria is a low purine diet and high intake of fluids. Because the solubility of xanthine is relatively independent of 4 urinary pH, urine alkalinization has no effect (in contrast to patients with uric acid lithiasis) (8, 9) .
There is a need to identify new agents that can prevent the development of xanthine crystals in the urine of patients with xanthinuria.
Materials and methods

Reagents and solutions
Xanthine (X), 1-methylxanthine (1-MX), 3-methylxanthine (3-MX), 7-methylxanthine 
Results
We studied the effect of 10 compounds on xanthine crystallization in synthetic urine ( Figure 1 ). Three of these compounds -1-MX, 7-MX, and 3-MX -significantly inhibited xanthine crystallization, and the others had no effects at the highest tested concentrations ( Figure 2 ). We also examined the possible synergistic effects of these 3 inhibitors. The results indicated additive, not synergistic, effects
We used SEM to examine the formation of crystals with and without 7-MX, 3-MX, and mixtures of 3-MX and 7-MX ( Figure 3) . The results show that these inhibitors slowed the rate of crystallization and reduced the abundance of crystalline nucleation; these treatments thereby reduced the formation of crystalline material and large crystals with well-developed faces. Our results clearly demonstrate the efficacy of three inhibitors of xanthine crystallization in artificial urine.
Discussion
Our results indicate that 1-MX, 7-MX, and 3-MX significantly inhibited xanthine crystallization in vitro. Moreover, the delay in time for induction of crystallization was dependent on the concentration of each inhibitor. It is important to note that HX, TP, PX, TB, CF, 1-MU, and 1,3-DMU had no significant effects on xanthine crystallization. This selective inhibition of xanthine crystallization among these structurally similar compounds is notable. Thus, among the xanthines studied, only methyl xanthines are incorporated into the crystalline network of xanthine. The incorporation of any of these 3 inhibitors into the xanthine crystal lattice modifies the structure of some layers, 7 thereby increasing the Gibbs free energy , and slowing the growth of the crystal.
Because xanthine solubility is relatively insensitive to urinary pH, we performed all inhibition studies at a pH of 6.0. Interestingly, TB is also very effective inhibitor of uric acid crystallization (10), although CF, PX, and TP have no effect on uric acid crystallization. This demonstrates the importance of the position of the methyl group on the efficacy of an inhibitor.
It is important to consider that two of the inhibitors of in vitro xanthine crystallization identified here are major metabolites of theobromine. In particular, after TB consumption, 20% is excreted as TB, 21.5% as 3-MX, and 36% as 7-MX. In contrast, 1-MX is not a metabolite of TB; instead, after consumption of caffeine, 19% is excreted as 1-MX (11) . TB is present in high amounts in chocolate and cocoa (12) , but has been less studied than other methylxanthines because it has less of an effect on the central nervous system than other xanthines. Extrapolation of previous in vivo data (11, 12) leads to the estimate that daily intake of only 200 mg of TB would lead to excretion of 43 mg of 3-MX and 72 mg of 7-MX. These amounts, in accordance with the results presented here, could significantly inhibit the formation of xanthine crystals in urine, and therefore prevent the development of renal xanthine calculi in patients with xanthinuria.
Our results indicate that two metabolites of TB -7-methylxanthine and 3methylxanthine -can inhibit xanthine crystallization, and therefore have high clinical potential for prevention of nephrolithiasis in patients with xanthinuria. Clinical trials of patients with xanthinuria are necessary to document the in vivo effects of TB consumption. 
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